Min H. Shin
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46.
Journal: Immune network
Published: June 08, 2024
Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
Journal: Molecular cancer
Published: September 28, 2023
Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+T-dependent CTL/NK cell activation.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 08, 2022
Hypoxia-Driven HIF-1α Activation Reprograms Pre-Activated NK Cells towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways.
Journal: Cancers
Published: March 19, 2021
Ectopic Expression of Human Thymosin β4 Confers Resistance to Legionella pneumophila during Pulmonary and Systemic Infection in Mice.
Journal: Infection and immunity
Published: November 23, 2020
Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
Journal: International journal of molecular sciences
Published: March 01, 2020
Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients.
Journal: Frontiers in immunology
Published: October 16, 2018
CD160 serves as a negative regulator of NKT cells in acute hepatic injury.
Journal: Nature communications
Published: May 23, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026